Published in JAMA on February 12, 1997
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol (2008) 2.22
The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med (2001) 2.09
Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med (2014) 2.00
Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol (2009) 1.89
Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population. Cancer Manag Res (2011) 1.81
Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ (1998) 1.77
[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging (2011) 1.67
Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol (2015) 1.44
The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ (2000) 1.30
Prostate cancer in elderly men. Rev Urol (2008) 1.19
Active surveillance for prostate cancer: trials and tribulations. World J Urol (2008) 1.15
What is low-risk prostate cancer and what is its natural history? World J Urol (2008) 1.09
The laminin binding integrin alpha6beta1 in prostate cancer perineural invasion. J Cell Physiol (2010) 1.06
Prostate cancer: 2. Natural history. CMAJ (1998) 1.06
The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ (2000) 1.02
Racial differences in PSA screening interval and stage at diagnosis. Cancer Causes Control (2010) 1.02
The Swedish prostate cancer paradox. JAMA (1997) 0.92
Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res (1999) 0.92
Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl (2015) 0.90
Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol (2010) 0.88
Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics (2009) 0.88
Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer Manag Res (2010) 0.88
The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res (2012) 0.88
Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring. J Natl Cancer Inst Monogr (2012) 0.87
Effectiveness and cost-effectiveness of prognostic markers in prostate cancer. Br J Cancer (2003) 0.86
Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram. Urology (2009) 0.86
Tissue biomarkers for prostate cancer radiation therapy. Curr Mol Med (2012) 0.84
Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group. Curr Oncol (2008) 0.81
Role of radical prostatectomy for high-risk prostate cancer. Korean J Urol (2010) 0.81
Managed care market share and primary treatment for cancer. Health Serv Res (2006) 0.81
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2015) 0.79
Smoking and prostate cancer survival and recurrence. Asian J Androl (2011) 0.78
Fifteen-year survival with prostate cancer in Sweden. JAMA (1997) 0.78
Treatment modalities for Māori and New Zealand European men with localised prostate cancer. Int J Clin Oncol (2015) 0.77
Perineural invasion and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2017) 0.76
Management of localized prostate cancer. Rev Urol (2004) 0.75
Prostate biopsy sampling causes hematogenous dissemination of epithelial cellular material. Dis Markers (2014) 0.75
What is the risk posed by prostate cancer? J Natl Cancer Inst Monogr (2012) 0.75
Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida. Am J Mens Health (2013) 0.75
Effect of intervention on decision making of treatment for disease progression, prostate-specific antigen biochemical failure and prostate cancer death. Health Expect (2012) 0.75
Non-Steroidal Anti-Inflammatory Drugs, Variation in Inflammatory Genes, and Aggressive Prostate Cancer. Pharmaceuticals (Basel) (2010) 0.75
Clinical Evidence: Non-metastatic prostate cancer. West J Med (1999) 0.75
Prostate cancer (early). BMJ Clin Evid (2006) 0.75
Prostate cancer in senior adults: over- or undertreated? Wien Med Wochenschr (2009) 0.75
[Radiotherapy for prostate cancer]. Wien Med Wochenschr (2007) 0.75
Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med (1999) 17.30
Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut (2005) 7.35
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer (1987) 6.20
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Prepregnancy weight and the risk of adverse pregnancy outcomes. N Engl J Med (1998) 5.66
Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol (2000) 4.83
The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med (1996) 4.81
Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA (1998) 4.65
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA (1992) 4.31
Evidence of prenatal influences on breast cancer risk. Lancet (1992) 4.25
The relation between survival and age at diagnosis in breast cancer. N Engl J Med (1986) 4.21
Transient increase in the risk of breast cancer after giving birth. N Engl J Med (1994) 4.08
Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05
Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med (1980) 4.03
Infections as a major preventable cause of human cancer. J Intern Med (2000) 3.96
Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. N Engl J Med (1996) 3.79
The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med (1989) 3.77
Cell-surface glycosaminoglycans. Annu Rev Biochem (1984) 3.68
Stressful life events and Graves' disease. Lancet (1991) 3.63
Adhesion and cytoskeletal organisation of fibroblasts in response to fibronectin fragments. EMBO J (1986) 3.54
Should the mission of epidemiology include the eradication of poverty? Lancet (1998) 3.42
Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA (2001) 3.37
Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden. BMJ (1998) 3.34
Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med (1999) 3.31
Evaluating gastric cancer misclassification: a potential explanation for the rise in cardia cancer incidence. J Natl Cancer Inst (1999) 3.13
Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst (1998) 3.10
Overweight as an avoidable cause of cancer in Europe. Int J Cancer (2001) 2.88
Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J Natl Cancer Inst (1994) 2.81
Gastro-oesophageal reflux symptoms, oesophagitis and Barrett's oesophagus in the general population: the Loiano-Monghidoro study. Gut (2008) 2.79
Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet (2000) 2.75
Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst (1996) 2.71
Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet (2000) 2.69
Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet (2000) 2.65
Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology (1993) 2.64
10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol (1999) 2.64
Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer (1990) 2.61
The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer (2000) 2.58
Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet (1990) 2.58
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst (1996) 2.57
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control (1997) 2.52
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology (1991) 2.51
Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. Lancet (1983) 2.51
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol (1997) 2.46
Beta 1 integrin-dependent and -independent polymerization of fibronectin. J Cell Biol (1996) 2.44
Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health (2009) 2.44
Increasing cancer risk in younger birth cohorts in Sweden. Lancet (1993) 2.39
Lack of beta 1 integrin gene in embryonic stem cells affects morphology, adhesion, and migration but not integration into the inner cell mass of blastocysts. J Cell Biol (1995) 2.39
Testicular cancer in nine northern European countries. Int J Cancer (1994) 2.32
Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer. Br J Cancer (1999) 2.31
Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer (1989) 2.30
The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology (1997) 2.29
Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst (1996) 2.29
Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study. J Natl Cancer Inst (1990) 2.22
Structure of the pericellular matrix: association of heparan and chondroitin sulfates with fibronectin-procollagen fibers. Cell (1982) 2.20
Isolation of the pericellular matrix of human fibroblast cultures. J Cell Biol (1979) 2.19
Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun (2001) 2.18
No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut (2000) 2.16
Survival in breast cancer diagnosed between mammographic screening examinations. Lancet (1986) 2.12
Perinatal measles infection and subsequent Crohn's disease. Lancet (1994) 2.11
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol (1998) 2.09
Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. Eur J Surg Oncol (2002) 2.09
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer (2006) 2.09
Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol (1989) 2.07
Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst (1997) 2.06
Response rate to mailed epidemiologic questionnaires: a population-based randomized trial of variations in design and mailing routines. Am J Epidemiol (1998) 2.06
[Meta-analysis is a good help for literature review. It makes the analysis of earlier studies more efficient and more objective]. Lakartidningen (1999) 2.02
Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagn Imaging Clin Med (1985) 2.02
Pesticides and cancer. Cancer Causes Control (1997) 2.00
Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst (1997) 1.98
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer (1999) 1.98
Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease? J Intern Med (2007) 1.97
Epigenetic modulation at birth - altered DNA-methylation in white blood cells after Caesarean section. Acta Paediatr (2009) 1.95
[Problems of interpretation in vascular surgery]. Lakartidningen (1993) 1.94
Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med (1998) 1.91
Cessation of smoking after myocardial infarction. Effects on mortality after 10 years. Br Heart J (1983) 1.90
Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst (2001) 1.90
Detection of preinvasive cancer of the cervix and the subsequent reduction in invasive cancer. J Natl Cancer Inst (1993) 1.87